

Site-Specific Mutation of *Staphylococcus aureus* VraS Reveals a Crucial Role for the VraR-VraS Sensor in the Emergence of Glycopeptide Resistance[∇]

Elena Galbusera,^{1†} Adriana Renzoni,^{2†} Diego O. Andrey,² Antoinette Monod,² Christine Barras,² Paolo Tortora,¹ Alessandra Polissi,¹ and William L. Kelley^{2*}

Dipartimento di Biotechnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy,¹ and Service of Infectious Diseases, University Hospital and Medical School of Geneva, 4 Rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland²

Received 26 May 2010/Returned for modification 22 August 2010/Accepted 13 December 2010

An initial response of *Staphylococcus aureus* to encounter with cell wall-active antibiotics occurs by transmembrane signaling systems that orchestrate changes in gene expression to promote survival. Histidine kinase two-component sensor-response regulators such as VraRS contribute to this response. In this study, we examined VraS membrane sensor phosphotransfer signal transduction and explored the genetic consequences of disrupting signaling by engineering a site-specific *vraS* chromosomal mutation. We have used *in vitro* autophosphorylation assay with purified VraS[64-347] lacking its transmembrane anchor region and tested site-specific kinase domain histidine mutants. We identified VraS H156 as the probable site of autophosphorylation and show phosphotransfer *in vitro* using purified VraR. Genetic studies show that the *vraS*(H156A) mutation in three strain backgrounds (ISP794, Newman, and COL) fails to generate detectable first-step reduced susceptibility teicoplanin mutants and severely reduces first-step vancomycin mutants. The emergence of low-level glycopeptide resistance in strain ISP794, derived from strain 8325 (*ΔrsbU*), did not require a functional σ^B , but *rsbU* restoration could enhance the emergence frequency supporting a role for this alternative sigma factor in promoting glycopeptide resistance. Transcriptional analysis of *vraS*(H156A) strains revealed a pronounced reduction but not complete abrogation of the *vraRS* operon after exposure to cell wall-active antibiotics, suggesting that additional factors independent of VraS-driven phosphotransfer, or σ^B , exist for this promoter. Collectively, our results reveal important details of the VraRS signaling system and predict that pharmacologic blockade of the VraS sensor kinase will have profound effects on blocking emergence of cell wall-active antibiotic resistance in *S. aureus*.

Staphylococcus aureus is a major human pathogen that causes a variety of diseases ranging from relatively minor skin infections to invasive and systemic disease with significant morbidity and mortality (17, 44). Of particular concern are *S. aureus* strains carrying one of several allotypes of a mobile genetic element, the SCCmec cassette, which encodes *mecA*, and a low-affinity penicillin-binding protein variant, PBP2A (12). The expression of PBP2A renders *S. aureus* insensitive to a broad range of β -lactams, including methicillin, hence the name MRSA (for methicillin-resistant *S. aureus*). Various MRSA strains have become endemic in hospitals and in the community prompting worldwide efforts for detection and infection control.

Glycopeptide antibiotics (teicoplanin and vancomycin) are considered first-line drugs for the treatment of infections due to MRSA. The emergence of resistance (most often termed reduced sensitivity) to glycopeptides poses a major challenge to the treatment of MRSA infections since few clinically proven and effective alternative therapies exist (29).

Altered sensitivity to glycopeptides occurs by two mechanisms termed exogenous and endogenous. The exogenous

mechanism (VanA type) conferring high-level resistance (vancomycin MIC ≥ 16 μ g/ml) occurs by the horizontal acquisition of the *vanA* multigene complex from *Enterococcus faecalis* encoded on Tn1546 and results in the alteration of peptidoglycan terminal stem peptide from D-Ala-D-Ala to D-Ala-D-Lac, a structure to which glycopeptides no longer bind efficiently and therefore fail to block transglycosylase and transpeptidase cell wall cross-linking (47, 57). Worldwide, only a few examples of VRSA have been reported (55).

In contrast, endogenous resistance to glycopeptides is much more prevalent. *S. aureus* displaying intermediate glycopeptide resistance (termed VISA if referring to vancomycin-intermediate *S. aureus* and GISA for glycopeptide-intermediate *S. aureus* encompassing both vancomycin and teicoplanin) are thought to arise stepwise from so-called heterogenous (hVISA and hGISA) precursor populations through selection of mutation(s) during the course of exposure to glycopeptides (28, 29, 43, 47). Rare subpopulations of bacteria displaying higher levels of resistance presumably serve as a reservoir driving the eventual emergence of glycopeptide resistance. Subpopulations of this type are difficult to detect, and no routine clinical laboratory tests exist that are standardized and reliable for their detection (29, 61).

The MIC breakpoint defining the transition from sensitive to intermediate resistant for glycopeptide intermediate-resistant *S. aureus* (GISA and VISA) is not universally agreed upon;

* Corresponding author. Mailing address: Service of Infectious Diseases, University Hospital and Medical School of Geneva, 4 rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland. Phone: (4122) 379 5651. Fax: (4122) 379 5702. E-mail: william.kelley@hcuge.ch.

† E.G. and A.R. contributed equally to this study.

∇ Published ahead of print on 20 December 2010.

however, relatively minor alterations in reduced sensitivity to glycopeptides (minor changes in MIC) are now frequently associated with clinical failure, requiring recourse to alternative pharmacotherapy (29).

The genetic basis of endogenous glycopeptide resistance is poorly understood. Mutation in genes such as *tcaA*, *graRS*, and *vraRS* have been described and are known to be causal or strongly correlated to the emergence of VISA and GISA (15, 30, 45, 48, 53). In some, but not all cases, morphological changes associated with the emergence of glycopeptide resistance include a thickened cell wall, reduced cross-linking, and decreased autolytic activity, suggesting that complex alterations in cell wall biosynthesis and turnover underlie the resistance mechanism (27, 47, 57).

Transcriptomic studies demonstrated that an encounter with cell wall-active antibiotics elicits a cell wall stress response in *S. aureus* (22, 40, 46, 49, 51, 73). The precise mechanisms that are responsible for the detection of cell wall damage are also poorly understood, and there are known significant interstrain variations (49).

In several studies, the transcriptional induction of the *vraRS* two-component sensor (TCS) system, which is part of a four-gene operon, is significantly induced after encounter with cell wall-active drugs such as oxacillin, vancomycin, teicoplanin, and D-cycloserine (22, 40, 49, 69, 77). The *vraRS* operon is also strongly induced after reduced transcription of *pbp2*, which encodes the bifunctional penicillin-binding protein PBP2 (22). The VraRS TCS is highly conserved in the low-percent G+C Gram-positive family *Firmicutes*. In *S. aureus*, the VraRS TCS is thought to regulate numerous genes, some necessary for cell wall biosynthesis and proteolytic quality control (40). At least two other *S. aureus* TCS systems—WalKR (YycFG) and GraRS—have been implicated in modulating resistance to cell wall-active antibiotics (16, 18, 30, 53, 63).

TCS systems are widespread in bacteria and represent environmental sensing systems that integrate a broad range of input stimuli to effector proteins, often including transcription factors (20, 21). A typical TCS system is composed of a membrane sensor histidine kinase and a cognate response regulator. Environmental signal captured by the receptor kinase results first in histidine autophosphorylation. In a second step, phosphotransfer from the histidine kinase to a conserved aspartate in the receiver domain of the cognate response regulator ultimately culminates in alterations in downstream gene expression, or altered enzymatic activity, appropriate to the applied stimulus.

In the present study, we dissected the VraRS phosphotransfer sensing mechanism. We identified the key elements of VraS-VraR phosphotransfer *in vitro* and examined genetic consequences *in vivo* by using a site-specifically engineered *vraS* autophosphorylation-defective chromosomal point mutation. Our results reveal a crucial role for VraS-VraR signaling in mediating the emergence of endogenous glycopeptide resistance.

MATERIALS AND METHODS

Bacterial strains and plasmids. The strains and plasmids used in the present study are listed in Table 1. Antibiotics and their suppliers were as follows: teicoplanin (Sanofi Aventis), vancomycin (Sandoz), and oxacillin, D-cycloserine, and carbenicillin (Sigma).

Cloning and purification of recombinant VraR and VraS proteins. The open reading frame of the *vraR* gene (SA1700 using the N315 ordered sequence tag numbering [41]) and the nucleotide region encoding the cytoplasmic domain of the *vraS* gene (corresponding to amino acids 65 to 347), hereafter referred to as VraS_{cyt}, were amplified by the PCR using *S. aureus* genomic DNA and primers indicated in Table 2. Fragments of 884 bp (*vraS*) and 650 bp (*vraR*) were cleaved with KpnI and PstI and cloned into the KpnI and PstI sites of pKSII+Bluescript, respectively. After sequence verification, the fragments were excised with NdeI-PstI and cloned into the *Escherichia coli* expression vector pTYB12 (New England Biolabs). Recombinant VraR and VraS_{cyt} proteins were then purified by using an N-terminal chitin affinity tag (Impact System; New England Biolabs). *E. coli* strain ER2566 containing pTYB12-VraR and pTYB12-VraS_{cyt} was grown in Luria-Bertani medium containing carbenicillin at 100 µg/ml until reaching an optical density at 600 nm of 0.4, induced with 0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside), and incubated for an additional 6 h at 30°C with vigorous shaking. Bacteria were harvested by low-speed centrifugation and resuspended in buffer containing 0.1% Tween 20, followed by affinity chromatography and intein-mediated proteolytic cleavage of the affinity tag with 50 mM dithiothreitol (DTT) according to the manufacturer's recommendations. Thiol-induced intein cleavage resulted in the N-terminal attachment of three additional amino acids (Ala-Gly-His) for VraR and four amino acids (Ala-Gly-His-Met) for VraS_{cyt} upstream of Ser65. Cleaved protein was eluted from the chitin beads, and the supernatant was concentrated and diafiltered using Centricon-10 spin columns. Protein concentrations assuming monomer molecular weights predicted from the amino acid composition were determined using Bradford reagent (Bio-Rad) and a bovine serum albumin standard. Recombinant proteins were stored at 4°C and were stable for at least 6 months.

QuikChange PCR mutagenesis (Stratagene) was used to create additional protein expression vectors by a similar strategy as described above for mutants VraR-D55A, VraS_{cyt}-H156A, and VraS_{cyt}-H238A (Table 2). All protein expression vector constructs were sequence verified prior to use. This purification strategy was used for the preparation of each mutant recombinant protein.

Autophosphorylation and phosphotransfer assay. To assess histidine autophosphorylation, 5 µM concentrations of either VraS_{cyt}, VraS_{cyt}-H156A, or VraS_{cyt}-H238A were incubated with 20 µCi of [³²P]ATP (Hartmann Analytics, FP-301, 111 TBq/mmol) at 22°C in a 70-µl labeling reaction containing 25 mM Tris-HCl (pH 7.0), 2.5 mM MgCl₂, 100 mM KCl, 0.1 mM DTT, 5% glycerol, and 20 µM cold ATP. Aliquots (10 µl) were removed after 5, 15, and 45 min and transferred to an equal volume of 2× sodium dodecyl sulfate (SDS) sample loading buffer and applied to 12% polyacrylamide-SDS protein gels (without heating). Protean II minigels (Bio-Rad) were electrophoresed at 11 W for 2 to 3 h. The gels were dried and autoradiographed (Amersham Hyperfilms). For phosphotransfer reactions between VraS and VraR, a VraS_{cyt} or VraS_{cyt}-H238A labeling protocol identical to that described above was used. After 45 min of VraS autophosphorylation, 40 µl was mixed with either purified VraR or with VraR-D55A to a final concentration of 17.5 µM. Aliquots (10 µl) were removed and mixed with an equal volume of 2× SDS sample buffer and applied to SDS protein gels as described above. Control phosphorylation reactions run in parallel and stained with Coomassie brilliant blue showed that all recombinant proteins were stable under the conditions of the *in vitro* assay.

Total RNA extraction. Overnight bacterial cultures were diluted 1:100 and grown at 37°C for 1 h in Mueller-Hinton broth (MHB) with shaking. When indicated, oxacillin (1 µg/ml; ISP794 MIC = 2 µg/ml; thus, conducted at 0.5 MIC) was added, and bacteria were grown for an additional hour. Bacteria were harvested, and RNA extraction and verification of the absence of contaminating DNA was performed as described previously (59). Purified RNA samples were analyzed by using the RNA NanoLab chip on a 2100 Bioanalyzer (Agilent, Palo Alto, CA).

Real-time RT-PCR. mRNA levels were determined by quantitative RT-PCR (qRT-PCR) by using a one-step reverse transcriptase qPCR master mix kit (Eurogentec, Seraing, Belgium), as described previously (59). Appropriate *vraR* and *vraS* primers and probes were designed by using Primer Express software (version 1.5; Applied Biosystems) and obtained from Eurogentec. The mRNA levels of target genes extracted from the different strains were normalized to 16S rRNA levels, which were assayed in each round of qRT-PCR as internal controls as described previously (74). The statistical significance of strain-specific differences in normalized cycle threshold (C_T) values of each transcript was evaluated by using a Student paired *t* test, and data were considered significant when *P* was <0.05.

Northern blotting. For transcript analysis, 6 µg of total RNA was separated in a 1% agarose formaldehyde gel and blotted onto a nylon membrane (Hybond-N Amersham) using 20× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate) buffer (Quantum Biotechnologies) with a semidry blot apparatus (Bio-

TABLE 1. Bacterial strains and plasmids used in this study

Strain or plasmid	Relevant genotype or characteristics ^a	Source or reference(s)
Strains		
<i>E. coli</i>		
ER2566	IPTG-inducible T7 RNA polymerase restriction-deficient DNA cloning strain	New England Biolabs
DH5 α		Gibco-BRL
<i>S. aureus</i>		
COL	MRSA, <i>rsbU</i> ⁺	24
RN4220	8325-4, r ⁻ m ⁺ , restriction-defective laboratory strain	38
Newman	ATCC 25904, MSSA, <i>rsbU</i> ⁺	1
MB211	8325, (<i>rsbUVW-sigB</i>) ⁺ , <i>tetL</i> nearby	23
MB212	8325, Δ <i>rsbUVW-sigB::ermB</i>	39
ISP794	8325, <i>pig-131 rsbU</i> mutant	60, 67
ALC1001	RN6390 <i>sigB::Tn551</i>	13
ALC2057	RN6390 <i>sarA::kan</i>	14
AR850	ISP794, Δ <i>rsbUVW-sigB::ermB</i>	This study
AR851	ISP794, <i>sigB::Tn551</i>	This study
AR852	ISP794, (<i>rsbUVW-sigB</i>) ⁺ , <i>tetL</i> nearby	This study
AR756	ISP794, <i>vraS</i> Δ 2-160:: <i>ermB</i>	This study
AR769	ISP794, <i>vraS</i> (H156A), Kan ^r nearby	This study
AR758	ISP794, Kan ^r within intergenic region SA1699- <i>vraR</i>	This study
AR943	ISP794, <i>tetK</i> within intergenic region SA1699- <i>vraR</i>	This study
AR828	ISP794, <i>vraS</i> (H156A), Kan ^r nearby, Φ 11 transduction from AR769	This study
AR878	ISP794, <i>vraS</i> (H156A), Kan ^r nearby + pAM1483	This study
AR872	ISP794, <i>vraS</i> (H156A), Kan ^r nearby + pAM902	This study
AR848	Newman, <i>vraS</i> (H156A), Kan ^r nearby, Φ 11 transduction from AR769	This study
AR868	COL, <i>vraS</i> (H156A), Kan ^r nearby, Φ 80 α transduction from AR769	This study
Plasmids		
pCL84	<i>tetK</i> ; <i>S. aureus geh</i> locus integrating plasmid	42
pUC18	Multicopy <i>E. coli</i> cloning vector	76
pUC19-MuSupF	Amp ^r mini-Mu transposon	26
pEC2	<i>ermB</i> cassette	11
pMK4	<i>E. coli-S. aureus</i> shuttle vector; Amp ^r Cam ^r	70
pBT2	<i>E. coli-S. aureus</i> thermosensitive shuttle vector; Amp ^r Cam ^r	11
pTYB12	N-terminal fusion Impact intein and chitin-binding domain plasmid	New England Biolabs
pKSII+Bluescript	Routine multicopy <i>E. coli</i> cloning vector	Stratagene
pAM1118	pKS+II <i>VraS</i> _{cyt} (NdeI-PstI)	This study
pAM1158	pKS+II <i>VraR</i> (NdeI-PstI)	This study
pEG1129	pTYB12- <i>VraS</i> _{cyt} (NdeI-PstI)	This study
pEG1	pTYB12- <i>VraS</i> _{cyt} H156A	This study
pEG2	pTYB12- <i>VraS</i> _{cyt} H238A	This study
pEG1055	pTYB12- <i>VraR</i> (Nde-Pst)	This study
pEG3	pTYB12- <i>VraR</i> -D55A	This study
pAR712	pBT2, <i>vraS</i> -Kan ^r -SA1699 intergenic ts shuttle vector	This study
pAR907	pBT2, <i>vraS-tetK</i> -SA1699 intergenic ts shuttle vector	This study
pAM1284	pBT2, <i>vraS</i> Δ [2-160>:: <i>ermB</i> ts shuttle vector	This study
pAR747	pBT2, <i>vraS</i> (H156A), Kan ^r nearby ts shuttle vector	This study
pAM1483	pMK4, 3.3-kb entire <i>vraR</i> operon and upstream promoter region, KpnI-PstI	This study
pAM1246	pKS+II, 3.3-kb entire <i>vraR</i> operon and upstream promoter region, KpnI-PstI	This study
pAM902	pMK4, pGlyS <i>gfpuv4</i>	72

^a Cam^r, chloramphenicol resistance; Amp^r, ampicillin resistance; Kan^r, kanamycin resistance.

Rad). The membrane was prehybridized with QuikHyb buffer (Stratagene) for 2 h at 65°C. An [α -³²P]UTP (Hartmann Analytics, FP-110, 15 TBq/mmol)-labeled *vraR* riboprobe was generated from pAM1158. After plasmid linearization with Acc65I and gel purification, an [α -³²P]UTP-labeled complementary antisense transcript was produced by *in vitro* transcription using T7 polymerase essentially as described previously (35). Unincorporated nucleotide was removed by passage over a microspin ProbeQuant G-50 column (GE Healthcare). The riboprobe mixture was treated with DNase I (Promega RQ1) to eliminate template DNA, extracted with phenol-chloroform-isoamyl alcohol (25:24:1), and precipitated with ethanol in the presence of 16 μ g of glycogen carrier. The pellet was washed with ice-cold 70% ethanol, dried, and resuspended in a minimal volume of Tris-EDTA. An aliquot was tested for probe purity on a 6% polyacrylamide 8 M urea sequencing gel. The prehybridized membrane was incubated overnight with the *vraR* riboprobe at 65°C in the same QuikHyb buffer.

Washes were done as follows: a first wash at 50°C with 2 \times SSC-0.1% SDS for 15 min, a second wash with 1 \times SSC-0.1% SDS for 15 min at 65°C, and then three washes with 0.1 \times SSC-0.1% SDS for 15 min at 70°C. The membrane was transferred to 3MM paper without drying, sealed, and autoradiographed (Amersham Hyperfilms).

Construction of AR756 containing a *vraS* disruption. To facilitate the construction of a site-specific codon change *VraS* H156A by allelic exchange, a chromosomal *vraS* disruption mutant was first constructed by deletion of the *vraS* coding sequence corresponding to amino acids 2 to 160 (inclusive) and insertion of an erythromycin resistance gene using the temperature-sensitive vector pBT2 (11). Briefly, a 1,076-bp upstream fragment and a 1,185-bp downstream fragment were separately amplified by using the primer pairs presented in Table 2; the products were then mixed and reamplified with the outside primers to create the fusion PCR-generated internal deletion of *vraS* and cloned into pUC18-digested

TABLE 2. Oligonucleotide PCR primers used in this study

Gene, mutant, protein, or method	Primer or probe	Primer sequence (5'-3') ^a
VraR wild-type protein	VraR-Kpn-Nde VraR-Pst	<u>GGGGTACCAAGGAGGAACACATATGACGATTAAGTATTG</u> <u>CAAACCTGCAGCTATTGAATTAATTATGTTGGAATGC</u>
VraR-D55A protein	VraR D55A-A VraR D55A-B	GATTTAATTTTAAATGGCTTACTTATGGAAG CTTCATAAGTAAAGCCATTAATAATTAATC
VraS _{cyt} wild-type protein	VraS _{cyt} -KpnNde PCR VraS _{cyt} -Pst PCR	<u>GGGGTACCAAGGAGGAACACATATGGGTTTCGGTACTCGCATACAAAATC</u> <u>CAAACCTGCAGTTAATCGTCATACGAATCCTC</u>
VraS-H156A protein	VraS H156A-A VraS H156A-B	GCTCGAGAACTTGCCGATTCTGTTAGTC GACTAACAGAATCGGCAAGTTCTCGAGC
VraS-H238A protein	VraS H238A-A VraS H238A-B	ATGAAAGTTGTGGCTGAAATACAAGATTTTAAAG CTTTAAAATCTTGTATTTTCAGCCACAACCTTTCAT
VraSΔ[2-160]: <i>ermB</i>	SA1703 Kpn-Bam Primer 2 Bam Primer 3 Bam SA1699 <i>staEco</i> -Pst	<u>GGGGTACCGGATCCATGAACTATGTTGAAACGTTATATTGAACAG</u> <u>CGGGATCCGTTTCATCGATAAATCACCTCTACG</u> <u>CGGGATCCAGCAACTTTTTGCGGCAAGTATGA</u> <u>CGGAATTCCTGCAGATGTGCAAAAATCACTCTTCTTCAAAAATACC</u>
VraS-H156A chromosomal mutant	SA1703KpnBamHI SA1699EcoPstI	<u>GGGGTACCGGATCCATGAACTATGTTGAAACGTTATATTGAACAG</u> <u>CGGAATTCCTGCAGATGTGCAAAAAGGATCACTCTTCTTCAAAAATACC</u>
Kan marked <i>vraR</i> -SA1699 intergenic	3BKpnBamHI 12ABgl2 12BBgl2 SA1699EcoPstI	<u>GGGGTACCGGATCCAGCAACTTTTTGCGGCAAGTATGATGC</u> <u>GAAGATCTCGTAAGTAACCTTTTCTTAATTCGATACG</u> <u>GAAGATCTCCAATCACAATATAACATCAAATAGACAC</u> <u>CGGAATTCCTGCAGATGTGCAAAAAGGATCACTCTTCTTCAAAAATACC</u>
Upstream <i>vraR</i> operon promoter	EYKpn Tet marker upF Tet marker downR Kan marker upF Kan marker downR	<u>GGGGGTACCACCTTTGATCCAAAAGACAAAACA</u> <u>CGGGATCCGCTTCACAGAAATTCTAGAAC</u> <u>ACGCGTCCGACTTTTATTACCTACAACCTCTTTA</u> <u>CGGGATCCGATAAACCCAGCGCAACCATTTG</u> <u>CGGGATCCATCGATACAAAATTCCTCGTAGG</u>
qRT-PCR	VraR-450 forward VraR-535 reverse VraR-473T (TAMRA-FAM)	TGCTTACAGAACGAGAAATGGAAA CCGTTTTAATAGTAATATGCGATGCA TGATTGCGAAAAGTTACTCAAATCAAGAAAT

^a Underlined regions represent restriction enzyme sequences.

by using KpnI and PstI. The erythromycin resistance *ermB* cassette was obtained by BamHI digestion of a mini-Mu transposon derivative of pUC19-MuSupF (26) harboring the *ermB* gene subcloned with linkers from pEC2 (11). The BamHI *ermB* fragment was cloned into the unique BglII site. A plasmid with the transcriptional orientation of *ermB* oriented in the same sense as the native *vraR* operon transcript was chosen, digested with KpnI, and partially digested with PstI, and then the 3.7-kb fragment was cloned into pBT2 to yield pAM1284. Plasmid pAM1284 was electroporated into the restriction-defective strain RN4220 and then transferred by electroporation into ISP794, selecting for erythromycin resistance at 30°C. ISP794 containing pAM1284 was grown overnight at 30°C, followed by growth with applied marker selection for 6 days with dilution passages at 42°C, a nonpermissive temperature for pBT2 replication. Bacteria were plated on agar containing 5 µg of erythromycin/ml and then replica streaked on 15-µg/ml chloramphenicol plates to screen for chloramphenicol-sensitive colonies. Double-crossover events corresponding to *vraS* gene disruption was confirmed by PCR. The resulting strain was named AR756.

Generation of AR769 containing the *vraS*(H156A) mutant. The site-specific chromosomal two-nucleotide change for the creation of *vraS*(H156A) was constructed using the thermosensitive plasmid pBT2 as follows. A KpnI-BglII overlap PCR fragment of ~2,700 bp was amplified from ISP794 using the primers SA1703KpnBamHI, H156A-B, H156A-A, and 12ABgl2 (Table 2). The overlap PCR fragment spanning the region from SA1703 gene to the *vraR*-SA1699 intergenic region contains the nucleotide changes in positions 466 (C to G) and 467 (A to C) of the *vraS* open reading frame, resulting in the H156A codon change. A second downstream PCR fragment was amplified by using the primer pair 12BBgl2 and SA1699EcoPst (Table 2) incorporating BglII and PstI restric-

tion sites covering ~1,300 bp from the *vraR*-SA1699 intergenic region and the adjacent SA1699 gene. The fragments were cloned together in a three-piece ligation with KpnI-PstI-digested pBT2. The unique BglII restriction site thus engineered in the *vraR*-SA1699 intergenic region was used to insert a kanamycin resistance marker obtained by PCR amplification from strain ALC2057 and incorporating terminal BamHI restriction sites (60). The site-specific *vraS*(H156A) codon change gene targeting plasmid was named pAR747 and was fully sequence verified.

Plasmid pAR747 was passaged through the nonrestricting strain RN4220, followed by recovery and electroporation into AR756, selecting for kanamycin resistance (Kan^r) at 30°C. A single colony was isolated and subjected to kanamycin selection for 6 days with regular dilution and subculture passages at 42°C. Bacteria were plated on agar containing 40 µg of kanamycin/ml and then replica streaked on 15-µg/ml chloramphenicol and 5-µg/ml erythromycin plates to screen for the Kan^r and erythromycin-sensitive (Ery^s) double-crossover events corresponding to the expected *vraS* allelic exchange. A single colony was grown and confirmed by PCR and sequencing. The resulting strain harboring *vraS*(H156A) and its nearby linked Kan^r marker to facilitate bacteriophage-mediated cotransduction was named AR769. Bacteriophage Φ80α was used to backcross the kanamycin-linked *vraS*(H156A) allele to ISP794 to yield AR828 (>95% cotransduction). For both AR769 and AR828, the entire chromosomal 3.3-kb *vraR* four-gene operon, including 600 bp of upstream promoter sequence from the SA1703 ATG start codon, was sequence verified. Both strains had only the desired *vraS*(H156A) codon change. Bacteriophage Φ80α and Φ11 were used to backcross the kanamycin-linked *vraS*(H156A) allele to strains COL and New-

man, yielding strains AR868 and AR848, respectively. The presence of the *vraS(H156A)* allele in each derivative strain was verified by sequencing.

Construction of AR758 and AR943 containing a kanamycin- or tetracycline-marked wild-type *vraR* operon. Identical targeted insertions of only the kanamycin resistance gene, or a tetracycline resistance gene, inserted nearby the *vraR* operon in the intergenic region between *vraR* and SA1699, were obtained using pBT2 as described above. Briefly, the regions 1,200 bp downstream and 1,300 bp upstream from chromosomal location 1946712 (using sequence coordinates based on N315 annotation [41]) were amplified by using the primer pairs described in Table 2. The kanamycin resistance marker was obtained by PCR amplification as described above. A BglII tetracycline resistance marker cassette was obtained as described previously (60). The desired double-crossover events were identified by screening for kanamycin/tetracycline-resistant but chloramphenicol-sensitive colonies. Correct insertion of the markers into the intergenic region was confirmed by PCR and sequencing.

Constructions of *rsbU*⁺ and *sigB* mutant derivatives of ISP794. The wild-type *rsbU*⁺ allele was restored in ISP794 by Φ 80 α bacteriophage transduction of the *tetL*-linked (*rsbUVW-sigB*)⁺ operon from donor strain MB211 and selection for tetracycline to yield AR852. ISP794 derivatives lacking a functional *sigB* gene (AR851) or disrupted for the entire *rsbUVW-sigB* operon (AR850) were constructed by Φ 80 α bacteriophage transduction using the donor strain ALC1001 or MB212, respectively. The restoration of *rsbU*⁺ in strain ISP794 was monitored both by the reappearance of yellow-orange pigmentation and by the presence of a functional σ^B monitored by using a qRT-PCR assay of the σ^B -dependent transcription of *asp23* (23, 39, 59).

Genetic assays for the emergence of glycopeptide resistance. Tests for the emergence of glycopeptide resistance were performed essentially as described previously (60). Briefly, overnight cultures of each strain to be tested were grown in MHB at 37°C with vigorous agitation. Each bacterial culture was subsequently normalized using sterile 0.9% (wt/vol) NaCl to McFarland standard 2 by using a Densimat apparatus (bioMérieux, France). Aliquots (500 μ l, 1.5×10^8 CFU) were spread on MHB agar containing various concentrations of freshly prepared teicoplanin or vancomycin, followed by incubation for 48 h at 37°C. To determine the relative efficiency of colony formation, serial dilutions of each culture were also plated on MHB plates without drug. For each strain background—ISP794, Newman, or COL—an emergence assay was performed using drug concentrations determined from pilot experiments to be at or above the broth macrodilution MIC. (Specifically, for teicoplanin these consisted of an ISP794 MIC of 1 to 2 μ g/ml, with an emergence assay performed at 2 μ g/ml; a Newman MIC of 1 to 2 μ g/ml [although the emergence assay was performed at 4 μ g/ml because pilot experiments showed that plates were nearly confluent if selection at 2 μ g/ml was applied]; and a COL MIC of 8 μ g/ml, with an emergence assay performed at 8 μ g/ml. For vancomycin, they were an ISP794 MIC of 1 to 2 μ g/ml, with an emergence assay performed at 2 μ g/ml; a Newman MIC of 2 to 4 μ g/ml, with an emergence assay performed at 2 μ g/ml; and a COL MIC of 2 to 4 μ g/ml, with an emergence assay performed at 2 μ g/ml.) Broth macrodilution MIC assays were performed as described previously (60). The data were tabulated as the number of viable colonies at each drug concentration tested and normalized per McFarland unit. The sum of CFU obtained on selective media in multiple experiments was reported, together with the mean emergence frequency defined as the ratio of normalized McFarland standard 1 CFU obtained on selective media divided by the number of CFU obtained on nonselective media. A subset of colonies was retested by replica plating on selective agar plates to estimate the percentage of false positives arising in each experiment. The raw data are reported without correction, and thus calculated emergence frequencies represent an upper limit.

Genetic complementation of *vraS(H156A)*. Strain AR828 was transformed with the empty *E. coli-S. aureus* shuttle plasmid pMK4 or pMK4 containing the entire cloned 3.3-kb *vraR* operon, together with native upstream promoter sequences (pAM1483). The genomic *vraR* operon fragment was obtained by PCR amplification using the primers EYKpn and *VraR*-Pst (Table 2) and *Pfx* polymerase (Invitrogen). The entire *vraR* operon was sequence verified using the appropriate primers. The functional restoration of induction of the *vraR* operon after challenge with oxacillin was performed as described above and monitored by qRT-PCR assay using a *vraR* TaqMan probe.

RESULTS

Prediction of the *VraS* H-box region and protein purification. Phylogenetic and functional studies of histidine kinase sensors have revealed several highly conserved motifs within the cytoplasmic kinase domain (21). The motifs comprise two

distinct domains: a HisKA domain containing the H-box and a conserved histidine residue that serves as the site of autophosphorylation, as well as a C-terminal domain termed HATPase within which are found boxes named N1, G, F, G2, and G3 that comprise the ATP-binding pocket (54).

Multiple sequence alignment using T-Coffee and CLUSTAL W2 algorithms (<http://www.expasy.org/tools/proteome>) were performed using the *S. aureus* *VraS* sequence and a panel of bacterial HK sensors. We identified one region, ARELH₁₅₆DSVSQ, which was similar to the H-box region of eight HK sensors subclassified as type III (36). In addition, sequence context inspection of all other histidines revealed a second potential histidine autophosphorylation site, VVH₂₃₈EI, which was highly similar to the VSH₂₄₉EI found in the *S. aureus* TCS HssRS system (68). A schematic diagram summarizing the predicted domain architecture of *VraS* is shown in Fig. 1.

We cloned the region comprising the predicted cytoplasmic domain of *VraS*, amino acids 65 to 347, hereafter referred to as *VraS*_{cyt}. The N-terminal 64 amino acids of *VraS* are very rich in hydrophobic residues, and this region is thought to comprise the transmembrane anchor sequence (Fig. 1). The precise topological configuration of the transmembrane region is unknown, as are the amino acids responsible for sensing external signals. To purify *VraS*_{cyt}, we designed PCR primers (Table 2) that incorporated both NdeI and PstI restriction sites appropriately positioned to permit cloning in pTYB12 (NEB). A recombinant hybrid *VraS*_{cyt} protein was produced in *E. coli* as an N-terminal intein fusion. Protein was purified by chitin affinity chromatography, cleaved *in situ* using DTT, eluted, and concentrated (see Materials and Methods). Thiol-induced cleavage resulted in the release of *VraS*_{cyt} containing four additional N-terminal amino acids: Ala, Gly, and His due to the intein self-cleavage recognition sequence, together with a Met introduced by the NdeI restriction site. A similar strategy was used to purify two variants of *VraS*_{cyt} in which histidines H156 and H238 had been separately replaced by alanine and named H156A and H238A (Fig. 1).

As a substrate for the detection of phosphotransfer by *VraS*_{cyt}, we used the same intein fusion protein strategy to purify wild-type *VraR* and a point mutant, *VraR*-D55A. Purified *VraR* and *VraR*D55A also possessed an additional N-terminal three amino acids, Ala-Gly-His, after thiol cleavage.

Aliquots of purified proteins were examined by Coomassie blue staining after electrophoresis in 12% polyacrylamide-SDS gels and judged to be >99% pure (Fig. 2). Purified wild-type and mutant *VraS*_{cyt} proteins all comigrated with an apparent mass of 34 kDa, which is consistent with the predicted 34-kDa molecular mass for this fragment. Purified wild-type *VraR* and *VraR*-D55A both comigrated in SDS-PAGE with an apparent molecular mass of 22 kDa, which is slightly smaller than the predicted 24 kDa for this fragment. Purified proteins were stable for at least several months at 4°C.

Determination of the site of *VraS* autophosphorylation. To examine the ability of each *VraS*_{cyt} protein to undergo autophosphorylation *in vitro*, samples were incubated in the presence of [γ -³²P]ATP, and aliquots were removed at various times, resolved on 12% polyacrylamide SDS gels, dried, and autoradiographed. The results are shown in Fig. 3A.

We observed a progressive increase in the intensity of radiolabeled wild-type *VraS*_{cyt} indicating autophosphorylation that




FIG. 1. Schematic diagram of VraS and VraR highlighting their domain architecture and the location of amino acids mutated in the present study. The predicted transmembrane region (TM), histidine kinase (HisKA), and histidine kinase ATP-binding domain (HATPase) are shown. VraS_{cyt} indicates the point of truncation used for the purification of the cytoplasmic and soluble portion of the protein used in the present study. The VraR response regulator is depicted and shows the receiver domain and position of phosphorylated aspartate, along with the C-terminal DNA-binding domain. The sequence alignment shows the H-box sequence context of VraS-H156, together with other conserved motifs within the ATP-binding domain. Sequences used were from Swiss-Prot accession: *Staphylococcus aureus* VraS, Q99SZ7; *Bacillus subtilis* LiaS, O32198; *Escherichia coli* UhpB, P09835; and *Haemophilus influenzae* NarQ, P44604.

reached an apparent plateau at 45 min. We observed a similar autophosphorylation of VraS_{cyt} H238A, which also showed a plateau after 45 min of incubation. The relative intensity of VraS_{cyt} and H238A autophosphorylation seen in the representative autoradiogram is most likely due to experimental conditions, or perhaps to altered protein specific activity. We did not further explore the exact cause of this discrepancy. In contrast, to the results obtained with VraS_{cyt} and H238A, we observed no detectable autophosphorylation of the H156A variant under identical conditions and replicate experiments.

We conclude from this analysis that VraS H156 is essential for autophosphorylation of the purified VraS_{cyt} fragment *in vitro* and that this site most probably represents the site of autophosphorylation. The arrangement and position of conserved amino acid residues in the N, G1, G2, and G3 regions of the VraS cytoplasmic domain fragment are coincident when comparing VraS alignment with other sensor kinase proteins such as *Escherichia coli* NarX and UhpB or *Haemophilus influenzae* NarQ (Fig. 1). The absence of an F region, together with the 108-amino-acid spacing between H156 and N strongly




FIG. 2. Purified VraR and VraS and their indicated mutant derivatives used in the present study. Proteins were resolved on 12% polyacrylamide-SDS gels and stained with Coomassie brilliant blue. Molecular mass standards are indicated in kilodaltons for the marker ladder.




FIG. 3. *In vitro* autophosphorylation and phosphotransfer assay using purified VraS and VraR. (A) VraS autophosphorylation time course assay in the presence of [γ -³²P]ATP. Reactions were assembled for the indicated times and applied to 12% polyacrylamide-SDS gels, dried, and autoradiographed. Wild-type VraS lacking the N-terminal transmembrane domain VraS_{cyt} and two purified histidine mutants, H156A and H238A, are shown. (B) VraS-VraR phosphotransfer assay. Autophosphorylation reactions were performed as described for panel A, and then VraR was added. Aliquots were removed at the indicated times and resolved on SDS-protein gels as described above. Note that a minor phosphorylated degradation product of VraS migrates at a position above phosphorylated VraR. S, VraS; R, VraR.




FIG. 4. Schematic showing the various genetic steps used for the construction of a chromosomal mutant encoding *vraS*(*H156A*) and marked with a nearby kanamycin resistance cassette in the *VraR*-*SA1699* (N315 ordered sequence tag numbering) intergenic region. A second strain harboring only the kanamycin resistance marker, but otherwise wild type for the entire *VraSR* four-gene operon, was designed in parallel. A thermosensitive shuttle plasmid, pAR747, was introduced into AR756. The correct double-crossover event yielded the desired *vraS*-*H156A* mutation by allelic exchange. The *vraS*(*H156A*) allele was then backcrossed into strain ISP794 by bacteriophage-mediated transduction using selection for the tightly linked nearby kanamycin marker to give AR828. The entire operon and upstream promoter sequences were completely sequence verified. Arrows indicate the transcription direction. *Kpn* and *Pst* denote the positions of the restriction sites used for the construction of pAR747 targeting vector.

suggests the classification of *VraS* as HK subtype type III and kinase type unorthodox (36).

***VraS* histidine kinase phosphotransfer assay.** Alignment of response regulators from multiple bacteria has consistently revealed a highly conserved acidic pocket positioned at the top of the characteristic $\alpha_5\beta_5$ protein fold of the receiver domain. An aspartate side chain within the pocket serves as an acceptor for phosphotransfer reaction from the cognate histidine kinase receiver domain. Inspection of the *VraR* domain revealed that D55A was most likely the site of phosphorylation. Using purified proteins and *in vitro* phosphotransfer assay, we demonstrated that phosphorylated *VraS*_{cyt} can transfer its phosphate to *VraR* but not to *VraR*-D55A (Fig. 3B). While the present study was in progress, *VraR*-D55A was independently identified by mass spectrometry as the site of *VraR* phosphorylation (3), thus confirming these results. Collectively, these findings define key molecular details of the essential amino acid residues, *VraS*-H156 and *VraR*-D55, comprising the phosphorelay network of the *VraRS* TCS system.

Targeted engineering of *vraS*(*H156A*) point mutation in the *S. aureus* chromosome. To examine the functional consequences of uncoupling *VraS*-*VraR* phospho-signaling *in vivo*, we next constructed *S. aureus* strains (AR769 and AR828) in which the *vraS*(*H156A*) mutation tagged with a nearby kanamycin resistance marker was stably introduced into the bacterial chromosome. Another strain, AR758, containing only the kanamycin marker within the *VraR*-*SA1699* intergenic region, but otherwise wild type for the entire *vraSR* operon, was designed in parallel. The two-step strategy used for the genetic engineering by allelic exchange of this targeted codon mutation is depicted in Fig. 4.

A design feature that permitted efficient screening for the kanamycin-linked *vraS*(*H156A*) mutation in strain AR769 was the prior construction of an intermediate strain, AR756, that contained an internal deletion within *vraS* (Fig. 4B). Kanamycin selection with the thermosensitive pAR747 targeting plasmid resulted in a subset of colonies having lost the *ermB* marker by allelic exchange, thus guaranteeing the

chromosomal insertion of the desired *vraS(H156A)* mutation (Fig. 4B).

Growth curves for ISP794, AR758, and the mutant strains AR769 and AR828 were identical and indicated that under our routine laboratory conditions, neither the introduction of a kanamycin marker in the *VraR-SA1699* intergenic region nor the H156A codon change in *VraS* resulted in detectable altered fitness (data not shown). Strains AR769 and AR828 were both used interchangeably for subsequent *in vivo* experiments.

Northern blot analysis. To assess the effect of *VraS-VraR* phosphotransfer uncoupling by the H156A mutation *in vivo*, transcriptional induction of the *vraR* operon was monitored by Northern blot and qRT-PCR analysis for strains ISP794 and AR828 after challenge with subinhibitory amounts of cell wall-active antibiotics.

Using a radiolabeled *vraR* probe, we observed a strong transcriptional induction of the *vraR* operon in the presence of 0.5 MIC oxacillin as an inducer (Fig. 5A). We detected multiple distinct bands by this Northern blot analysis, including the longest transcript (2.7 to 3.0 kb) sufficient to encode the entire operon (22, 40, 77). In contrast, transcriptional induction was severely reduced in the mutant strain AR828. Similar results were obtained with subinhibitory concentrations of D-cycloserine and teicoplanin as cell wall stress inducers (data not shown).

Quantification of *vraR* mRNA levels by qRT-PCR analysis confirmed the oxacillin-stimulated transcriptional induction of the *vraR* operon. A small, but significant ($P < 0.05$) residual level of transcriptional induction (~2-fold) was observed in the *vraS(H156A)* mutant strain compared to its uninduced control level (Fig. 5B). This result suggests the possibility that additional transcriptional regulatory circuits exist for this operon that do not depend upon *VraS*-mediated signal transduction.

We next repeated the qRT-PCR assay using RNA extracted from strains harboring the multicopy plasmid pMK4, or pMK4 containing the entire 3.3-kb *vraR* operon including native upstream promoter sequences (pAM1483). We observed strong transcriptional induction of the *vraR* operon in the mutant strain harboring pAM1483, but not pMK4 vector alone, in the presence of subinhibitory oxacillin as described above (data not shown). We conclude that the *vraS(H156A)* mutation is recessive and that only the *vraS(H156A)* mutation accounts for the observed loss of transcriptional induction in the experiments described above.

Effect of *vraS(H156A)* on the frequency of emergence of reduced sensitivity first step glycopeptide mutants. To test the functional consequences *in vivo* of uncoupling *VraS-VraR* phospho-signaling, we next examined whether the mutation detectably altered the MIC, or the frequency with which resistant colonies appeared on agar plates supplemented with various amounts of glycopeptide antibiotics. We reasoned that uncoupling the *VraS-VraR* phosphotransfer sensory system would significantly affect the detection of cell wall stress and thus alter or abolish the emergence of glycopeptide-resistant mutants.

We addressed this hypothesis using three *S. aureus* strain backgrounds: ISP794 (an 8325 derivative defective in *rsbU* and consequently lacking a normal alternative stress sigma factor σ^B pathway), Newman (*rsbU*⁺), and COL (an *rsbU*⁺ MRSA strain). The teicoplanin and vancomycin MICs were determined for ISP794, Newman, and COL, and the emergence




FIG. 5. Transcriptional analysis showing the effects of uncoupling of *VraS* phosphotransfer. (A) Northern blot analysis showing strong oxacillin-induced induction of *vraR* operon transcription in wild-type cells but severe reduction in the *vraS(H156A)* mutant. Note that the *vraR* operon is autoregulated. The 2.7-kb band encodes the entire four-gene operon. Estimated lengths of additional transcripts are indicated that may represent strong pause sites or partial transcript degradation. Ethidium bromide-stained 16S and 23S rRNAs are shown as loading controls. (B) Quantitation of *VraR* mRNA levels by qRT-PCR analysis showing that oxacillin-stimulated transcriptional induction of the *vraR* operon is severely reduced but not completely abolished by *vraS(H156A)*. An asterisk denotes Student two-tailed *t* test analysis of transcript levels in the presence or absence of oxacillin ($P < 0.05$) from three independent determinations.

assay was designed to detect the number of viable colonies arising on plates containing drug at the MIC determined for each parental strain (see Materials and Methods). We observed a significant MIC reduction in every case (Table 3). Measurement of the oxacillin MIC for the MRSA strain COL (MIC = 400 μ g/ml) and AR868 (MIC 100 μ g/ml) indicated that the *vraS(H156A)* mutation also significantly reduced methicillin resistance in this strain background.

It is worthwhile to emphasize that the MIC values we report

TABLE 3. Effect of *vraS(H156A)* mutation on glycopeptide MIC

Strain	MIC ($\mu\text{g/ml}$) ^a	
	Teicoplanin	Vancomycin
ISP794	1–2	1–2
AR828	0.5	0.5
Newman	1–2	2–4
AR848	0.5	0.5–1
COL	4–8	2–4
AR868	0.5	0.5–2

^a MIC assays were performed by using broth macrodilution. Note that discrepancies (ranges) have been indicated for glycopeptide MICs that are method dependent (75).

throughout our studies here were determined using broth macrodilution; this method may give higher values than other susceptibility testing methods. Indeed, a recent study conducted in our laboratory indicates that microdilution methods tend to underestimate glycopeptide resistance (75). Glycopeptide MIC values for both COL and Newman have also been shown to be sensitive to experimental conditions (7, 66). Some caution is warranted, therefore, for cross-comparison of MIC values in the published literature since it is becoming clear that inoculum size, growth medium, time of incubation, and method are important parameters that collectively impact reported MIC values.

Next, for each parental strain tested, we observed the consistent appearance of viable colonies on agar plates containing various amounts of teicoplanin or vancomycin in the emergence assay. The frequency of emergence was computed for each strain and defined as the ratio of the number of colonies appearing using a standardized bacterial inoculum applied to each plate (1.5×10^8 CFU) under selective (T_{MIC} or V_{MIC}) or nonselective (T_0 or V_0) conditions. We measured a frequency of viable colonies (defined hereafter as emergence) by this method predominantly in a range from 1.1×10^{-6} to 5.0×10^{-8} , depending upon the strain and applied selection (Table 4). Similar results were observed when vancomycin was used, although we noted that the emergence frequency was lower for this drug than for teicoplanin under our standard laboratory conditions.

Colonies that arise in our emergence assay are either false positives and do not grow under selective conditions upon

replating or represent stable mutants that do grow at or above the original selective conditions upon replating. We estimated the false-positive rate in multiple experiments by sampling subsets of colonies and determined it to be in the range of 5 to 20%. The tabular data we report, however, reflect the summated raw data from multiple independent experiments without correction for false-positive rate, which was not computed for every experiment. Thus, the resulting calculation of resistance frequencies yields an upper limit. In some cases, we also examined the spread of MIC values of colonies that arose during selection and which were classed as stable. For example, ISP794 selected for growth on MH agar plates in the presence of 2 μg of teicoplanin/ml gave rise to a range of MICs from 2 to 8 $\mu\text{g/ml}$ (data not shown). Thus, colonies that grow at the applied selection concentration and that are not false positive show MIC values at or above the drug concentration used for the initial applied selection.

In striking contrast to our results obtained with strains harboring a wild-type *vraS* allele, we never observed colonies arising in multiple independent trials using teicoplanin selection for any of the three strains tested containing the *vraS(H156A)* mutation. When using vancomycin selection, we did not observe the appearance of resistant colonies with strain ISP794; however, we did observe the appearance of several viable colonies derived from strains Newman or COL (Table 4). The appearance of these infrequent colonies, whose vancomycin resistance was confirmed by replating, indicated that during selection with vancomycin the *vraS(H156A)* mutation drastically reduced (by $>2 \log_{10}$) but did not entirely abolish the emergence of resistant colonies in these strain backgrounds. Control experiments with strains carrying only the kanamycin resistance marker in the *vraR*-SA1699 intergenic region showed equivalent emergence frequencies of drug-resistant colonies compared to parental strains, thus ruling out any deleterious role for this marker that could account for the observed abolition or significant reduction in viable CFU for strains AR828, AR848, and AR868 exposed to glycopeptides (data not shown).

To confirm that the abolition of the emergence of glycopeptide-resistant mutants was indeed the result of the *vraS(H156A)* mutation, we performed a complementation analysis using strains AR878 and AR872 containing multicopy plasmid pAM1483 encoding the entire four-gene *vraR* operon or containing pAM902 control vector harboring green fluorescent

TABLE 4. Effect of *vraS(H156A)* mutation on emergence of glycopeptide resistance

Strain	Description	Relevant genotype	Emergence ^a of:			
			Teicoplanin		Vancomycin	
			CFU Σ_{tot} (n)	FOE (T_{MIC}/T_0)	CFU Σ_{tot} (n)	FOE (V_{MIC}/V_0)
ISP794		MSSA, ΔrsbU	5591 (9)	1.1×10^{-6}	37 (3)	5.0×10^{-8}
AR828	ISP794, <i>vraS(H156A)</i>	MSSA, ΔrsbU	0 (9)	NC	0 (3)	NC
AR878	ISP794, <i>vraS(H156A)</i> , pAM1483	MSSA, ΔrsbU	238 (3)	6.6×10^{-7}	30 (3)	6.7×10^{-8}
AR872	ISP794, <i>vraS(H156A)</i> , pAM902	MSSA, ΔrsbU	0 (3)	NC	0 (3)	NC
Newman		MSSA, <i>rsbU</i> ⁺	504 (6)	4.0×10^{-7}	200 (3)	2.0×10^{-7}
AR848	Newman, <i>vraS(H156A)</i>	MSSA, <i>rsbU</i> ⁺	0 (6)	NC	1 (3)	7.6×10^{-10}
COL		MSSA, <i>rsbU</i> ⁺	626 (4)	8.0×10^{-7}	456 (3)	3.5×10^{-6}
AR868	COL, <i>vraS(H156A)</i>	MSSA, <i>rsbU</i> ⁺	0 (4)	NC	4 (3)	3.1×10^{-8}

^a The frequency of emergence (FOE) is expressed as the ratio of CFU under selective (T_{MIC} or V_{MIC}) and nonselective (T_0 or V_0) conditions computed as the mean from the indicated number (n) of independent experiments. Each emergence assay was performed using MH agar and 1.5×10^8 applied bacteria per plate. CFU were counted at 48 h and 37°C. False-positive rates of CFU detected in the emergence assay were found to be 5 to 20% depending upon the experiment. NC, not computed.

TABLE 5. Effect of alternative sigma factor *sigB* on the emergence of glycopeptide resistance

Strain	Description	Relevant genotype	CFU Σ_{tot} (<i>n</i>)	FOE ^a (T_2/T_0)	MIC ($\mu\text{g/ml}$) ^b	
					Teicoplanin	Vancomycin
ISP794		ΔrsbU	1,065 (3)	1.1×10^{-6}	1–2	1–2
AR850	ISP794, ΔsigB operon	$\Delta\text{rsbUVW sigB::ermB}$	280 (3)	3.5×10^{-7}	2	1
AR851	ISP794, ΔsigB	sigB::Tn551	633 (3)	8.0×10^{-7}	1	1
AR852	ISP794, rsbU^+	$(\text{rsbUVW-sigB})^+$, <i>tetL</i> nearby	>3,000 (3) ^c	$>3.0 \times 10^{-5d}$	2	2

^a The frequency of emergence (FOE) was determined as described in Table 4, footnote *a*.

^b Defined in Table 3, footnote *a*.

^c Viable counts on agar containing 2 μg of teicoplanin/ml were too high to accurately measure using these conditions compared to ISP794. More than 1,000 CFU were estimated in each experiment.

^d The value reported is an estimate of the lower limit using CFU data obtained under identical conditions for the frequency determined with ISP794.

protein (Table 4). The results revealed that restoration of wild-type *vraS* coding sequence concomitantly restored emergence of glycopeptide resistant mutants using either teicoplanin or vancomycin selection (Table 4). Similar results were obtained in a second type of complementation analysis without multicopy plasmid where we restored wild-type *vraS* in the ISP794 genetic background by allelic exchange using bacteriophage-mediated transduction from AR943 (data not shown).

Collectively, we conclude from these results that the VraS-VraR phosphotransfer uncoupling mutation *vraS(H156A)* abolished the detectable emergence of teicoplanin-resistant colonies and severely reduced the frequency of emergence of vancomycin resistant colonies. Since the *vraS(H156A)* mutation also alters COL resistance to oxacillin, we conclude that uncoupling VraS-VraR phosphotransfer impacts *S. aureus* response to at least two classes of antibiotics and can act both at the level of blocking emergence or altering the sensitivity profile of preexisting drug resistance.

Role of the alternative sigma factor σ^B in the emergence of glycopeptide resistance. The ISP794 strain and its derivatives used routinely in our laboratory (8, 60) and also extensively for studies of fluoroquinolone resistance (19) is a derivative of 8325 and carries an 11-bp deletion in *rsbU*. Because of this mutation, ISP794 possesses impaired transcriptional responses mediated by the alternative stress sigma factor σ^B . A functional σ^B is thought to play a role in glycopeptide resistance (5, 7), but its role in the early steps of emergence of drug resistance have not been previously examined. Therefore, to test what role, if any, σ^B played in the emergence of glycopeptide resistance in this strain background, we constructed three isogenic derivatives of ISP794: AR850, AR851, and AR852, which were characterized by deletion of the entire four-gene *rsbUVW-sigB* operon, disruption of the *sigB* alone, or restoration of rsbU^+ , respectively. Each strain was tested in multiple independent assays as described above. The results are shown in Table 5.

We observed that the deletion of the entire *rsbUVW-sigB* operon, or *sigB* alone, did not abolish the emergence of teicoplanin-resistant colonies. In contrast, when rsbU^+ was restored in ISP794, we noted dramatic enhanced emergence frequency compared to ISP794 (ΔrsbU) conducted under identical conditions. We conclude that a functional σ^B markedly enhances the emergence of glycopeptide resistance in this strain background but that σ^B is not absolutely required for resistant colonies to arise.

DISCUSSION

In this study, we have identified the amino acids, VraS H156 and VraR D55, involved in phosphotransfer signaling in the VraRS TCS, a sentinel system for cell wall stress in *S. aureus*. Importantly, we have found that three distinct strains—ISP794, Newman, and COL, each genetically engineered to harbor the mutation encoding autophosphorylation-defective VraS H156A—are unable to generate first step low-level teicoplanin resistance mutants at a detectable frequency. The mutation also abolished detectable first-step low-level vancomycin-resistant mutants in strain ISP794 and severely reduced the frequency of mutants in Newman and COL strains. Disruption of VraS-mediated signaling in these strains also significantly altered the MICs of both teicoplanin and vancomycin as measured by broth macrodilution and also significantly altered the oxacillin MIC in the MRSA strain COL.

A broad range of antibiotics provoke cell wall stress in *S. aureus* and transcriptional upregulation of the *vraSR* four-gene operon is a feature commonly observed (22, 40, 77). Recent study provides a mechanistic explanation since VraR binds directly to its own promoter and thus autoregulates itself (4). Besides extensive evidence from transcriptome and sequence analysis of clinical isolates that highlight the importance of VraRS for glycopeptide resistance (9, 16, 22, 32, 34, 40, 46, 49, 52, 56, 73), additional mutations in the *graRS* TCS or *tcaA* disruption promote glycopeptide resistance (10, 15, 30, 45, 48, 53). Transcriptional upregulation of the WalkR TCS is also associated with altered glycopeptide resistance (31). Considering our inability to isolate first-step mutants using strains carrying the *vraS(H156A)* mutation, it is tempting to speculate that a functional VraRS phosphotransfer signaling system is necessary for all, or certainly a majority, of pathways leading to the emergence of glycopeptide resistance. It is important to stress, nevertheless, that the emergence assay that we describe in the present study used selection at very low drug concentrations, and therefore the role of VraRS has not been systematically assessed under other selection conditions using, for example, higher drug concentrations.

Several recent studies also provide evidence for glycopeptide resistance arising as a consequence of genetic selection with antibiotics other than glycopeptides. For example, selection of *S. aureus* growth in the presence of imipenem or daptomycin has been shown to produce strains with altered glycopeptide resistance profiles (32, 33, 50). These results are also supported

by clinical case reports suggesting that the mechanisms responsible for altered sensitivity to daptomycin and the emergence of hVISA are related (37, 71). In light of these findings, it is conceivable that disruption of VraRS TCS signaling could also predictably attenuate the emergence of glycopeptide cross-resistance evoked by a nonglycopeptide drug encounter.

Derivatives of *S. aureus* strain 8325, such as ISP794 used in our study, are known to have an 11-bp deletion in *rsbU*, and consequently such strains display reduced availability of free σ^B , an alternative stress sigma factor that has been shown to regulate more than 200 genes in response to a variety of stress inducers (6, 23, 39). Free σ^B is sequestered by the anti-sigma factor RsbW and is thought to be released in times of stress by the anti-sigma factor RsbV, provided it is dephosphorylated by the RsbV-specific phosphatase, RsbU (65). The absence of a functional RsbU in 8325 derived strains thus explains the constitutive sequestration of σ^B by RsbW. Previous studies (5, 7) have hinted that σ^B controls gene(s) required for glycopeptide resistance in *S. aureus* and that teicoplanin exposure stress can select for enhanced σ^B activity. One recently identified σ^B -regulated gene contributing to reduced glycopeptide sensitivity is *spoVG*, although its mechanism of action in *S. aureus* remains to be clarified (64).

In our study, we examined the role of σ^B specifically at the level of the emergence of first step teicoplanin resistance mutants and found that strains derived from ISP794 lacking *sigB* (encoding σ^B) or the entire *rsbUVW-sigB* operon were still able to generate teicoplanin-resistant mutants, thus formally demonstrating that a functional σ^B was not strictly necessary for the emergence of glycopeptide resistance in this strain background. In contrast, the restoration of wild-type *rsbU* in ISP794, and thus the concomitant restoration of fully functional σ^B stress response, led to markedly enhanced emergence of teicoplanin resistance. Our inability to isolate first-step teicoplanin mutants in an ISP794 *rsbU*⁺ strain carrying *vraS(H156A)* indicates that disrupting VraRS signaling can apparently override any contribution to the emergence of low-level teicoplanin resistance dependent upon σ^B in this strain background.

Using quantitative transcript analysis, we have shown that the *vraS(H156A)* mutation abolishes most, but not all transcription induction of the *vraSR* operon after brief exposure to a subinhibitory amount of oxacillin to provoke cell wall stress. Only a single major transcription start site upstream of SA1703, the first open reading frame of the four-gene operon, has been detected by primer extension (77) and confirmed independently by our laboratory using 5' rapid amplification of cDNA ends (5'RACE; A. Renzoni, unpublished results). The *vraRS* operon is not known to be transcriptionally regulated by σ^B under any condition tested (6). We therefore believe that additional regulatory pathways exist for this promoter that are not governed by VraS-VraR phosphotransfer. Experiments to uncover these accessory regulatory factors are in progress.

The consequences of genetic disruption of *vraS* by insertional inactivation or by deletion of the entire *vraSR* coding region have been studied independently by several laboratories (9, 16, 22, 40, 51, 56, 77). These reports link the loss of function of VraRS to oxacillin resistance in C-MRSA, altered drug sensitivity profiles in a range of clinical MSSA and MRSA isolates, and disruption of VraR-dependent target gene acti-

vation such as *pbp2*. In addition, a growing inventory of clinical hVISA and GISA isolates that have been partially sequenced reveals numerous examples of missense mutations mapping in *vraS*, *vraR*, or SA1702 (16, 32–34, 52). How missense mutations such as VraS-I5N modify VraRS-dependent signaling and gene expression is unknown. A reasonable hypothesis is that such mutations result in enhanced activation of the VraRS signaling pathway, even in the absence of an external inducing signal such as drug stress. With the VraSR pathway set in an ON, or semi-ON state, the cells realign their cell wall biosynthetic machinery to survive in the presence of glycopeptide.

Our study clearly predicts that pharmacologically blocking VraS signaling by interfering with its sensor histidine kinase function will significantly block the emergence of glycopeptide resistance or restore fully, or partially, sensitivity to glycopeptide antibiotics in strains showing preexisting reduced sensitivity to these drugs. The idea of using kinase inhibitors to target bacterial TCS systems has been suggested for many years, especially in light of the fact that TCS systems are not found in humans (2, 25, 58, 62). Our genetic study reported here therefore provides a firm foundation for this strategy and further predicts that the efficacy of existing antistaphylococcal cell wall-active antibiotics might be prolonged if such kinase inhibitor compounds were to be ultimately identified and coadministered.

Evidence presented to date thus underscores the importance of the *vraRS* operon at the crossroads mediating *S. aureus* response to cell wall stress and cell wall-active antibiotics. The ensemble of downstream events that are regulated by VraR-dependent transcription may be quite extensive judging by the number of genes suspected to be regulated by this system. Additional response pathways mediated by other TCS systems (AgrAB, GraRS, and WalkR) and global regulators such as σ^B would appear to contribute to the establishment of endogenous glycopeptide resistance. By targeting the initial molecular features of the VraRS signaling response pathway at the onset of this multifactorial regulatory cascade, we strongly believe that emergence of glycopeptide resistance could be contained.

ACKNOWLEDGMENTS

This study was supported by Swiss National Science Foundation grant 3100A0-120428 (to W.L.K.), a Novartis Consumer Health Foundation postdoctoral fellowship grant (to A.R.), and an F. Hoffmann-La Roche M.D.-Ph.D. training grant (to D.O.A.). Portions of this study were financed by a student exchange fellowship from the Italian Ministry of Education and Research (E.G.).

We thank Markus Bischoff, Brigitte Berger-Bachi, Reinhold Bruckner, and Ambrose Cheung for generously providing strains and plasmids and members of the laboratory for their encouraging support and helpful comments on the manuscript.

REFERENCES

- Baba, T., T. Bae, O. Schneewind, F. Takeuchi, and K. Hiramatsu. 2008. Genome sequence of *Staphylococcus aureus* strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. *J. Bacteriol.* **190**:300–310.
- Barrett, J. F., and J. A. Hoch. 1998. Two-component signal transduction as a target for microbial anti-infective therapy. *Antimicrob. Agents Chemother.* **42**:1529–1536.
- Belcheva, A., and D. Golemi-Kotra. 2008. A close-up view of the VraSR two-component system: a mediator of *Staphylococcus aureus* response to cell wall damage. *J. Biol. Chem.* **283**:12354–12364.
- Belcheva, A., V. Verma, and D. Golemi-Kotra. 2009. DNA-binding activity of the vancomycin resistance associated regulator protein VraR and the role of phosphorylation in transcriptional regulation of the *vraSR* operon. *Biochemistry* **48**:5592–5601.

5. Bischoff, M., and B. Berger-Bachi. 2001. Teicoplanin stress-selected mutations increasing σ^B activity in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **45**:1714–1720.
6. Bischoff, M., et al. 2004. Microarray-based analysis of the *Staphylococcus aureus* σ^B regulon. *J. Bacteriol.* **186**:4085–4099.
7. Bischoff, M., et al. 2001. Involvement of multiple genetic loci in *Staphylococcus aureus* teicoplanin resistance. *FEMS Microbiol. Lett.* **194**:77–82.
8. Bisognano, C., et al. 2004. A RecA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in *Staphylococcus aureus*. *J. Biol. Chem.* **279**:9064–9071.
9. Boyle-Vavra, S., S. Yin, and R. S. Daum. 2006. The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **262**:163–171.
10. Brandenberger, M., M. Tschierske, P. Giachino, A. Wada, and B. Berger-Bachi. 2000. Inactivation of a novel three-cistronic operon *tcaR-tcaA-tcaB* increases teicoplanin resistance in *Staphylococcus aureus*. *Biochim. Biophys. Acta* **1523**:135–139.
11. Bruckner, R. 1997. Gene replacement in *Staphylococcus carnosus* and *Staphylococcus xyloso*. *FEMS Microbiol. Lett.* **151**:1–8.
12. Chambers, H. F., and F. R. Deleo. 2009. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat. Rev. Microbiol.* **7**:629–641.
13. Cheung, A. L., Y. T. Chien, and A. S. Bayer. 1999. Hyperproduction of alpha-hemolysin in a *sigB* mutant is associated with elevated SarA expression in *Staphylococcus aureus*. *Infect. Immun.* **67**:1331–1337.
14. Cheung, A. L., K. Schmidt, B. Bateman, and A. C. Manna. 2001. SarS, a SarA homolog repressible by *agr*, is an activator of protein A synthesis in *Staphylococcus aureus*. *Infect. Immun.* **69**:2448–2455.
15. Cui, L., J. Q. Lian, H. M. Neoh, E. Reyes, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **49**:3404–3413.
16. Cui, L., H. M. Neoh, M. Shoji, and K. Hiramatsu. 2009. Contribution of *vraSR* and *graSR* point mutations to vancomycin resistance in vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **53**:1231–1234.
17. DeLeo, F. R., and H. F. Chambers. 2009. Reemergence of antibiotic-resistant *Staphylococcus aureus* in the genomics era. *J. Clin. Invest.* **119**:2464–2474.
18. Dubrac, S., P. Bisicchia, K. M. Devine, and T. Msadek. 2008. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. *Mol. Microbiol.* **70**:1307–1322.
19. Fournier, B., R. Aras, and D. C. Hooper. 2000. Expression of the multidrug resistance transporter NorA from *Staphylococcus aureus* is modified by a two-component regulatory system. *J. Bacteriol.* **182**:664–671.
20. Galperin, M. Y. 2006. Structural classification of bacterial response regulators: diversity of output domains and domain combinations. *J. Bacteriol.* **188**:4169–4182.
21. Gao, R., and A. M. Stock. 2009. Biological insights from structures of two-component proteins. *Annu. Rev. Microbiol.* **63**:133–154.
22. Gardete, S., S. W. Wu, S. Gill, and A. Tomasz. 2006. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **50**:3424–3434.
23. Giachino, P., S. Engelmann, and M. Bischoff. 2001. σ^B activity depends on RsbU in *Staphylococcus aureus*. *J. Bacteriol.* **183**:1843–1852.
24. Gill, S. R., et al. 2005. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant *Staphylococcus aureus* strain and a biofilm-producing methicillin-resistant *Staphylococcus epidermidis* strain. *J. Bacteriol.* **187**:2426–2438.
25. Guarnieri, M. T., L. Zhang, J. Shen, and R. Zhao. 2008. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ. *J. Mol. Biol.* **379**:82–93.
26. Haapa, S., S. Taira, E. Heikkinen, and H. Savilahti. 1999. An efficient and accurate integration of mini-Mu transposons in vitro: a general methodology for functional genetic analysis and molecular biology applications. *Nucleic Acids Res.* **27**:2777–2784.
27. Hiramatsu, K. 2001. Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *Lancet Infect. Dis.* **1**:147–155.
28. Hiramatsu, K., et al. 1997. Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet* **350**:1670–1673.
29. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. *Clin. Microbiol. Rev.* **23**:99–139.
30. Howden, B. P., et al. 2008. Genetic analysis reveals a point mutation in the two-component sensor gene *graS* that leads to intermediate vancomycin resistance in clinical *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **52**:3755–3762.
31. Jansen, A., et al. 2007. Role of insertion elements and *ycyFG* in the development of decreased susceptibility to vancomycin in *Staphylococcus aureus*. *Int. J. Med. Microbiol.* **297**:205–215.
32. Katayama, Y., H. Murakami-Kuroda, L. Cui, and K. Hiramatsu. 2009. Selection of heterogeneous vancomycin-intermediate *Staphylococcus aureus* by imipenem. *Antimicrob. Agents Chemother.* **53**:3190–3196.
33. Kato, Y., T. Suzuki, T. Ida, and K. Maebashi. 2010. Genetic changes associated with glycopeptide resistance in *Staphylococcus aureus*: predominance of amino acid substitutions in YvqF/VraSR. *J. Antimicrob. Chemother.* **65**:37–45.
34. Kato, Y., et al. 2008. Microbiological and clinical study of methicillin-resistant *Staphylococcus aureus* (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance. *Int. J. Antimicrob. Agents* **31**:64–70.
35. Kelley, W. L., and C. Georgopoulos. 1997. Positive control of the two-component RcsC/B signal transduction network by DjlA: a member of the DnaJ family of molecular chaperones in *Escherichia coli*. *Mol. Microbiol.* **25**:913–931.
36. Kim, D., and S. Forst. 2001. Genomic analysis of the histidine kinase family in bacteria and archaea. *Microbiology* **147**:1197–1212.
37. Kirby, A., et al. 2009. In vivo development of heterogeneous glycopeptide-intermediate *Staphylococcus aureus* (hGISA), GISA, and daptomycin resistance in a patient with methicillin-resistant *S. aureus* endocarditis. *J. Med. Microbiol.* **58**:376–380.
38. Kreiswirth, B. N., et al. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. *Nature* **305**:709–712.
39. Kullik, I., P. Giachino, and T. Fuchs. 1998. Deletion of the alternative sigma factor sigmaB in *Staphylococcus aureus* reveals its function as a global regulator of virulence genes. *J. Bacteriol.* **180**:4814–4820.
40. Kuroda, M., et al. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in *Staphylococcus aureus*. *Mol. Microbiol.* **49**:807–821.
41. Kuroda, M., et al. 2001. Whole genome sequencing of methicillin-resistant *Staphylococcus aureus*. *Lancet* **357**:1225–1240.
42. Lee, C. Y., S. L. Buranen, and Z. H. Ye. 1991. Construction of single-copy integration vectors for *Staphylococcus aureus*. *Gene* **103**:101–105.
43. Liu, C., and H. F. Chambers. 2003. *Staphylococcus aureus* with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. *Antimicrob. Agents Chemother.* **47**:3040–3045.
44. Lowy, F. D. 1998. *Staphylococcus aureus* infections. *N. Engl. J. Med.* **339**:520–532.
45. Maki, H., N. McCallum, M. Bischoff, A. Wada, and B. Berger-Bachi. 2004. *tcaA* inactivation increases glycopeptide resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **48**:1953–1959.
46. McAleese, F., et al. 2006. Overexpression of genes of the cell wall stimulin in clinical isolates of *Staphylococcus aureus* exhibiting vancomycin-intermediate *S. aureus*-type resistance to vancomycin. *J. Bacteriol.* **188**:1120–1133.
47. McCallum, N., B. Berger-Bachi, and M. M. Senn. 2010. Regulation of antibiotic resistance in *Staphylococcus aureus*. *Int. J. Med. Microbiol.* **300**:118–129.
48. McCallum, N., A. K. Brassinga, C. D. Sifri, and B. Berger-Bachi. 2007. Functional characterization of TcaA: minimal requirement for teicoplanin susceptibility and role in *Caenorhabditis elegans* virulence. *Antimicrob. Agents Chemother.* **51**:3836–3843.
49. McCallum, N., G. Spehar, M. Bischoff, and B. Berger-Bachi. 2006. Strain dependence of the cell wall damage-induced stimulin in *Staphylococcus aureus*. *Biochim. Biophys. Acta* **1760**:1475–1481.
50. Mishra, N. N., et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **53**:2312–2318.
51. Muthaiyan, A., J. A. Silverman, R. K. Jayaswal, and B. J. Wilkinson. 2008. Transcriptional profiling reveals that daptomycin induces the *Staphylococcus aureus* cell wall stress stimulin and genes responsive to membrane depolarization. *Antimicrob. Agents Chemother.* **52**:980–990.
52. Mwangi, M. M., et al. 2007. Tracking the in vivo evolution of multidrug resistance in *Staphylococcus aureus* by whole-genome sequencing. *Proc. Natl. Acad. Sci. U. S. A.* **104**:9451–9456.
53. Neoh, H. M., et al. 2008. Mutated response regulator *graR* is responsible for phenotypic conversion of *Staphylococcus aureus* from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. *Antimicrob. Agents Chemother.* **52**:45–53.
54. Parkinson, J. S. 1995. Genetic approaches for signaling pathways and proteins, p. 9–24. *In* J. A. Hoch (ed.), *Two-component signal transduction*. ASM Press, Washington, DC.
55. Perichon, B., and P. Courvalin. 2009. VanA-type vancomycin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **53**:4580–4587.
56. Pietiainen, M., et al. 2009. Transcriptome analysis of the responses of *Staphylococcus aureus* to antimicrobial peptides and characterization of the roles of *vraDE* and *vraSR* in antimicrobial resistance. *BMC Genomics* **10**:429.
57. Pinho, M. G. 2008. Mechanisms of β -lactam and glycopeptides resistance in *Staphylococcus aureus*, p. 207–226. *In* J. A. Lindsay (ed.), *Staphylococcus molecular genetics*. Caister Academic Press, Norfolk, United Kingdom.
58. Qin, Z., et al. 2006. Structure-based discovery of inhibitors of the YycG

- histidine kinase: new chemical leads to combat *Staphylococcus epidermidis* infections. *BMC Microbiol.* **6**:96.
59. **Renzoni, A., et al.** 2004. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **48**:2958–2965.
 60. **Renzoni, A., et al.** 2009. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **53**:903–911.
 61. **Renzoni, A., W. L. Kelley, P. Vaudaux, A. L. Cheung, and D. P. Lew.** 2010. Exploring innate glycopeptide resistance mechanisms in *Staphylococcus aureus*. *Trends Microbiol.* **18**:55–56.
 62. **Roychoudhury, S., et al.** 1993. Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. U. S. A.* **90**:965–969.
 63. **Sass, P., and G. Bierbaum.** 2009. Native *graS* mutation supports the susceptibility of *Staphylococcus aureus* strain SG511 to antimicrobial peptides. *Int. J. Med. Microbiol.* **299**:313–322.
 64. **Schulthess, B., et al.** 2009. Functional characterization of the sigmaB-dependent *yabJ-spoVG* operon in *Staphylococcus aureus*: role in methicillin and glycopeptide resistance. *Antimicrob. Agents Chemother.* **53**:1832–1839.
 65. **Senn, M. M., et al.** 2005. Molecular analysis and organization of the sigmaB operon in *Staphylococcus aureus*. *J. Bacteriol.* **187**:8006–8019.
 66. **Sieradzki, K., and A. Tomasz.** 2006. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate *Staphylococcus aureus*-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible *S. aureus*. *Antimicrob. Agents Chemother.* **50**:527–533.
 67. **Stahl, M. L., and P. A. Pattee.** 1983. Confirmation of protoplast fusion-derived linkages in *Staphylococcus aureus* by transformation with protoplast DNA. *J. Bacteriol.* **154**:406–412.
 68. **Stauff, D. L., V. J. Torres, and E. P. Skaar.** 2007. Signaling and DNA-binding activities of the *Staphylococcus aureus* HssR-HssS two-component system required for heme sensing. *J. Biol. Chem.* **282**:26111–26121.
 69. **Steidl, R., et al.** 2008. *Staphylococcus aureus* cell wall stress stimulon *galacZ* fusion strains: potential for use in screening for cell wall-active antimicrobials. *Antimicrob. Agents Chemother.* **52**:2923–2925.
 70. **Sullivan, M. A., R. E. Yasbin, and F. E. Young.** 1984. New shuttle vectors for *Bacillus subtilis* and *Escherichia coli* which allow rapid detection of inserted fragments. *Gene* **29**:21–26.
 71. **Tenover, F. C., et al.** 2009. Characterisation of a *Staphylococcus aureus* strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. *Int. J. Antimicrob. Agents* **33**:564–568.
 72. **Tu Quoc, P. H., et al.** 2007. Isolation and characterization of biofilm formation-defective mutants of *Staphylococcus aureus*. *Infect. Immun.* **75**:1079–1088.
 73. **Utaida, S., et al.** 2003. Genome-wide transcriptional profiling of the response of *Staphylococcus aureus* to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. *Microbiology* **149**:2719–2732.
 74. **Vaudaux, P., et al.** 2002. Increased expression of clumping factor and fibronectin-binding proteins by *hemB* mutants of *Staphylococcus aureus* expressing small colony variant phenotypes. *Infect. Immun.* **70**:5428–5437.
 75. **Vaudaux, P., et al.** 2010. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **54**:3861–3870.
 76. **Yanisch-Perron, C., J. Vieira, and J. Messing.** 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* **33**:103–119.
 77. **Yin, S., R. S. Daum, and S. Boyle-Vavra.** 2006. *VraSR* two-component regulatory system and its role in induction of *pbp2* and *vraSR* expression by cell wall antimicrobials in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **50**:336–343.